Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective DOI: 10.1590/2175-8239-JBN-2024-0101pt Graphical Abstract Click to view Abstract GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014
On average, semaglutide treatment can range from several hundred to over a thousand dollars per month, depending on dosage, provider, and location
Efecto prolongado
The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire
B vitamins including B-12, pantothenic acid, choline, folic acid and others
More from the series Subscribe: Apple Podcasts Spotify Injectable peptide therapy, a controversial wellness trend that caught fire online in 2025, shows no signs of slowing down in 2026, despite an overwhelming lack of safety data